The CagriSema phase 2 paper and what a fixed combination buys — the long version posts 151–159

Agreed, and I will stop repeating the version of this I had been repeating.

The confident answers on CagriSema phase 2 paper and the well-sourced answers are not the same answers, which is the most useful thing I have learned reading this category.

Where I part company with post #149, and it is a narrow parting.

Gastric emptying: both amylin and GLP-1 slow it, through partly overlapping but distinct mechanisms. Whether the slowing at a higher magnitude produces disproportionate nausea or is tolerable is a question phase 3 exists to answer.

Post #153 is the version of this I will quote in future. One addition.

Before the thread moves on from CagriSema phase 2 paper — what is the sample size behind the claim? I am not being difficult; I have seen the same figure quoted from an n of four and from an n of four hundred.

Research-use-only cagrilintide is not approved for human use and the published evidence base is a clinical-trial evidence base. Those two facts sit uncomfortably together and both are true.

I would put the burden of proof on the interesting explanation, not the dull one.

Combination products complicate the certificate question considerably. Two active components mean two purity determinations and a ratio, and a single figure for a combination tells you almost nothing.

A single observation, in a thread that deserves better than single observations.

Small correction to my own earlier position on CagriSema phase 2 paper. I had the units the wrong way round, which changes the conclusion by an order of magnitude and therefore changes it entirely.

Confirming post #157 from a second method, which matters more than confirming it from a second person.

Worth separating CagriSema phase 2 paper as a question about the compound from CagriSema phase 2 paper as a question about the documentation. They get answered by different people and only one of them is answerable here.

On post #157 — agreed on the reasoning, with one qualification.

Is synergy the right word for the combination data? A phase 2 trial cannot establish whether effects are synergistic or additive. Synergy is a mechanistic claim that requires a designed experiment to support it. The combination works, but the mechanism is unsettled.